ASLAN Pharmaceuticals Limited (ASLN)

Market Cap	1.70M
Revenue (ttm)	12.00M
Net Income (ttm)	-35.03M
Shares Out	2.83M
EPS (ttm)	-14.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	806,352
Open	0.6300
Previous Close	0.7000
Day's Range	0.6000 - 0.7000
52-Week Range	0.4750 - 20.0800
Beta	1.40
Analysts	Strong Buy
Price Target	90.67 (+15,011.67%)
Earnings Date	Aug 9, 2024

About ASLN

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor α1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 4, 2018
• Employees: 35
• Stock Exchange: NASDAQ
• Ticker Symbol: ASLN
• Website: https://aslanpharma.com

Analyst Summary

According to 3 analysts, the average rating for ASLN stock is "Strong Buy." The 12-month stock price target is $90.67, which is an increase of 15,011.67% from the latest price.

Price Target

$90.67

(15,011.67% upside)

Analyst Consensus: Strong Buy